Struggling pharma companies to outsource clinical trial research

Falling revenue in some healthcare sectors means companies are making huge efforts to reduce R&D expenditure and increase profitability, and are outsourcing clinical trial activities to Contract Research Organizations (CROs) in order to achieve this, according to a new report by health care intelligence company GBI Research.

The new report suggests that the R&D productivity of top pharmaceutical companies has declined over recent years, as a result of increasingly stringent Food and Drug Administration regulations concerning the approval of new drugs. This will significantly affect pharmaceutical companies’ revenue generation, and will only encourage further use of CROs in future.